Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

Weekly ixazomib with lenalidomide‐dexamethasone (Rd) is feasible and has shown activity in newly diagnosed multiple myeloma (NDMM) patients. This phase 1/2 study (NCT01383928) evaluated the recommended phase 2 dose (RP2D), pharmacokinetics, safety and efficacy of twice‐weekly ixazomib plus Rd in NDM...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Haematol
Asıl Yazarlar: Richardson, Paul G., Hofmeister, Craig C., Rosenbaum, Cara A., Htut, Myo, Vesole, David H., Berdeja, Jesus G., Liedtke, Michaela, Chari, Ajai, Smith, Stephen D., Lebovic, Daniel, Raje, Noopur, Byrne, Catriona, Liao, Eileen, Gupta, Neeraj, Bacco, Alessandra Di, Estevam, Jose, Berg, Deborah, Baz, Rachid
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley and Sons Inc. 2018
Konular:
Haematological Malignancy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6055619/
https://ncbi.nlm.nih.gov/pubmed/29938772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.15394
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller